Clinical Trial of Electro-Acupuncture Preconditioning in Patients Underwent Heart Valve Replacement Surgery

Clinical Trial of The Myocardial Protective Effects of Repeated Electroacupuncture Preconditioning in Heart Valve Replacement Surgery

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00732459

Enrollment

Registered

2008-08-12

Start date

2007-01-31

Completion date

2008-12-31

Last updated

2008-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic Valve Disease

Keywords

myocardial protection, cardiac surgery, heart valve replacement

Brief summary

The purpose of this study is to investigate the protective effect of electro-acupuncture preconditioning in patients underwent cardiac surgery.

Detailed description

Heart valve replacement surgery has been proved to be an effective method in treating both regenerative and rheumatic valve disease. Current studies showed that cardiopulmonary bypass (CPB) and operation related myocardial injury, as indicated by the release of perioperative cardiac enzymes, is associated with worse patient morbidity and mortality after elective valve replacement surgery. Although the actual mechanism is still unclear, it has been shown that ischemic preconditioning is one potential strategy for reduction of myocardial injury in open heart surgery. Recently, Electro- acupuncture (EA) was proved to produced cerebral protective and antiarrhythmic effects by mimicking ischemic preconditioning. This study aims to assess whether electroacupuncture preconditioning is also effective in reducing myocardial injury in adults with acquired heart valve disease undergoing elective valve replacement surgery.

Interventions

DEVICEElectro-acupuncture preconditioning

electro-acupuncture

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

* patients who have the indication for aortic or mitral valve replacement * patients would like to accept the follow-up and sign the informed consent * patients with heart function of NYHA I-III degree.

Exclusion criteria

* pregnant or nursing women * comorbid with coronary artery disease * patients with heart function of NYHA IV degree * renal dysfunction with serum creatinine level\>or=2mg/dl(177umol/L) * anticipated life span \< 12 months * enrollment in other clinical trials at the same time not reaching the primary endpoint and probably interference the present trial.

Design outcomes

Primary

Measure	Time frame
late loss	12 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026